Data presented currently at IAS 2011 in Rome denote future application for resource-limited settings
Rome, Italy (PRWEB UK) 18 July 2011
The system, a new chronicle of the ‘HIV-TRePS’ service, was especially created by the HIV Resistance Response Database Initiative (RDI) to help guide treatment decisions in resource-limited settings where comparatively costly genotype insurgency tests are not customarily performed. It harnesses the power of P.C. models created over a few years using information from tens of thousands of patients to envision how an particular with HIV infection will reply to all the existing HIV drug combinations.
“I am gay to see this service launched today”, commented Dr. Julio Montaner, Past President of the International AIDS Society and Director of the BC Centre for Excellence in HIV AIDS, formed in Vancouver, Canada. “I have always been assured that the RDI’s network could be of leading worth in settings where resources are compelled or experience is limited. This unequivocally has the future to make a difference”.
The new network uses a set of computational models called pointless forests to make predictions from over 40 not similar pieces of information composed from roughly 16,000 patients in more than 20 countries. During practice the models achieved with an accurateness of roughly 75%. Results presented currently at IAS 2011 showed the models to be 68-69% exact with cases from Romania and South Africa, where HIV/AIDS is a leading dare and paltry resources do not often enable for genotyping.
Use of the network could help physicians prevent drug combinations that are reduction expected to work. Recent clinical studies indicate that they moreover have the future to help persist treatment options and resources by assisting to sustain manage of the pathogen without the must be review to newer and more costly drugs.
The RDI launched the initial chronicle of its HIV Treatment Response Prediction System (HIV-TRePS) in October 2010. That chronicle requires the results of a genotype test, that highlights the mutations in the viral genetic ethics that can result in insurgency to drugs. The new version, that does not require a genotype, performs with only a few commission points reduction accuracy, notwithstanding the no show of this information. The initial chronicle is in use by more than 350 illness caring professionals in 55 countries.
“We are exceedingly gratified to launch this innovative draw close to presaging treatment response without the need for a insurgency test”, commented Dr Brendan Larder, Scientific Chair of the RDI. “With the enlargement of HIV treatment worldwide, you hope this will infer to be a very utilitarian apparatus and you urge on people to try it out. We would moreover urge on treating physicians in countries that do not customarily run insurgency tests to send us their information so you can use them to make future network refinements and updates.”
The RDI is an independent, not-for-profit general investigate conspiring set-up in 2002 with the assignment to upgrade the clinical administration of HIV infection by the application of bioinformatics to HIV drug insurgency and treatment outcome data. Over the 9 years given its inception, the RDI has worked with many of the leading clinicians and scientists in the world to rise the world’s largest database of HIV drug insurgency and treatment outcome data, containing information from roughly 70,000 patients in more than 20 countries.
Note: HIV-TRePS is an experimental network intended for investigate use only. The predictions of the network are not intended to reinstate veteran medical caring and concern by a competent medical practitioner and hence the RDI does not agree to any shortcoming is to preference of drugs, the patient’s response to treatment or differences between the predictions and patients’ responses.
More information may be found at: .
For serve information contact:
Andrew Revell ( Executive Director , RDI) on +44 207 226 7314, +44 7967 126498 (mobile) or andrewrevell(at)hivrdi(dot)org
The subsequent to crew are existing for talk on request, by Andrew Revell above:
Dr Julio Montaner: Past President of the International AIDS Society and Director of the BC-Centre for Excellence in HIV AIDS, formed in Vancouver, Canada (time disparity –8 hours)
Dr Brendan Larder: Scientific Chairman of the RDI, Cambridge, UK
Dr Andrew Revell: Executive Director, RDI, London, UK
The RDI’s International Advisory Group
Dr Julio Montaner (BC Centre For Excellence in HIV/AIDS, Vancouver, Canada)
Dr Carlo Torti (University of Brescia, Italy)
Dr John Baxter (Cooper University Hospital, Camden, NJ, USA)
Dr Sean Emery (National Centre in HIV Epidemiology and Clinical Research, Sydney, Australia)
Dr Jose Gatell (Hospital Clinic of Barcelona, Spain)
Dr Brian Gazzard (Chelsea and Westminster Hospital, London, UK)
Dr Anna-Maria Geretti (Royal Free Hospital, London, UK)
Dr Richard Harrigan (BC Centre For Excellence in HIV/AIDS, Vancouver, Canada)
# # #
Andrew Revell
RDI
+44 7967 126498
Email Information
